{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:14:55Z","timestamp":1793070895214,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Epithelioid hemangioendothelioma (EHE) represents an ultra-rare, translocated vascular sarcoma with a heterogeneous course of disease. The optimal systemic treatment for patients with advanced EHE remains unclear. We sought to evaluate the value of pazopanib (PAZ) as a first-line treatment in metastatic EHE.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Thirteen patients with metastatic EHE and PAZ as a first-line treatment at our institution between 2012 und 2023 were reviewed and analyzed with regard to clinical outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>At a median follow-up of 51.4 months, the median progression-free survival (PFS) and overall survival (OS) were 35.1 and 53.8 months, respectively. In patients with documented prior tumor progression (<jats:italic>n<\/jats:italic>\u2009=\u200910), the median PFS and OS were 12.6 and 105 months, respectively. In patients with serosal effusion\/ systemic symptoms (<jats:italic>n<\/jats:italic>\u2009=\u20094), the median PFS and OS were 6.1 and 10.3 months. The clinical benefit rate of the overall cohort was 62% with no complete or partial responses. Two of four patients experienced a reduction of symptoms (pain and ascites reduction\/hemoptysis, respectively) under treatment with PAZ. Toxicity was mainly gastrointestinal and manageable with dose reductions. Permanent treatment interruption due to toxicity was necessary in one patient.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This is the first study to systematically report survival outcomes for PAZ as a first-line treatment in patients with metastatic EHE. PAZ is active and safe in patients with metastatic EHE and may be considered as an alternative to sirolimus for specific patient subgroups. RECIST criteria should be questioned for evaluation of treatment response in EHE.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00432-025-06208-8","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T07:42:52Z","timestamp":1745653372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["First-line pazopanib in patients with metastatic epithelioid hemangioendothelioma: a retrospective single-center analysis"],"prefix":"10.1007","volume":"151","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9801-3530","authenticated-orcid":false,"given":"Anton","family":"Burkhard-Meier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera Valerie","family":"Rechenauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vindi","family":"Jurinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Albertsmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hoberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Roland","family":"D\u00fcrr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kn\u00f6sel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang G.","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Mock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Pusztai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"V\u00f6lkl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars H.","family":"Lindner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorit","family":"Di Gioia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc M.","family":"Berclaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"key":"6208_CR1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mds237","volume":"24","author":"M Agulnik","year":"2013","unstructured":"Agulnik M, Yarber JL, Okuno SH et al (2013) An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol 24:257\u2013263. https:\/\/doi.org\/10.1093\/annonc\/mds237","journal-title":"Ann Oncol"},{"key":"6208_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.32074\/1591-951X-213","volume":"113","author":"CP Angelo Dei Tos","year":"2021","unstructured":"Angelo Dei Tos CP, Sbaraglia M, Bellan E, Dei Tos AP (2021) The 2020 WHO classification of soft tissue tumours: news and perspectives. Pathologica 113:70\u201384. https:\/\/doi.org\/10.32074\/1591-951X-213","journal-title":"Pathologica"},{"key":"6208_CR3","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/GCC.22073","volume":"52","author":"CR Antonescu","year":"2013","unstructured":"Antonescu CR, Le Loarer F, Mosquera JM et al (2013) Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer 52:775\u2013784. https:\/\/doi.org\/10.1002\/GCC.22073","journal-title":"Genes Chromosomes Cancer"},{"key":"6208_CR4","doi-asserted-by":"publisher","unstructured":"Blay JY, Piperno-Neumann S, Watson S et al (2023) Epithelioid hemangio-endothelioma (EHE) in NETSARC: the nationwide series of 267 patients over 12 years. Eur J Cancer 192. https:\/\/doi.org\/10.1016\/J.EJCA.2023.113262","DOI":"10.1016\/J.EJCA.2023.113262"},{"key":"6208_CR5","unstructured":"Cancer Institute N (2017) Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0"},{"key":"6208_CR6","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1002\/CNCR.28109","volume":"119","author":"C Chevreau","year":"2013","unstructured":"Chevreau C, Le Cesne A, Ray-Coquard I et al (2013) Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French sarcoma group (GSF\/GETO). Cancer 119:2639\u20132644. https:\/\/doi.org\/10.1002\/CNCR.28109","journal-title":"Cancer"},{"key":"6208_CR7","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/GCC.20886","volume":"50","author":"C Errani","year":"2011","unstructured":"Errani C, Zhang L, Sung YS et al (2011) A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer 50:644\u2013653. https:\/\/doi.org\/10.1002\/GCC.20886","journal-title":"Genes Chromosomes Cancer"},{"key":"6208_CR8","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1002\/CAM4.3807","volume":"10","author":"AM Frezza","year":"2021","unstructured":"Frezza AM, Ravi V, Lo Vullo S et al (2021) Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the world sarcoma network and a review of literature. Cancer Med 10:2645\u20132659. https:\/\/doi.org\/10.1002\/CAM4.3807","journal-title":"Cancer Med"},{"key":"6208_CR9","doi-asserted-by":"crossref","unstructured":"Gr\u00fcnwald V, Karch A, Schuler M et al (2020) Randomized comparison of pazopanib and doxorubicin as First-Line treatment in patients with metastatic soft tissue sarcoma age 60 years or older: results of a German intergroup study. In: Journal of Clinical Oncology","DOI":"10.1200\/JCO.20.00714"},{"key":"6208_CR10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1080\/0284186X.2016.1234068","volume":"56","author":"A Koll\u00e1r","year":"2017","unstructured":"Koll\u00e1r A, Jones RL, Stacchiotti S et al (2017) Pazopanib in advanced vascular sarcomas: an EORTC soft tissue and bone sarcoma group (STBSG) retrospective analysis. Acta Oncol (Madr) 56:88\u201392. https:\/\/doi.org\/10.1080\/0284186X.2016.1234068","journal-title":"Acta Oncol (Madr)"},{"key":"6208_CR11","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1378\/CHEST.11-0039","volume":"140","author":"K Lau","year":"2011","unstructured":"Lau K, Massad M, Pollak C et al (2011) Clinical patterns and outcome in epithelioid hemangioendothelioma with or without pulmonary involvement: insights from an internet registry in the study of a rare cancer. Chest 140:1312\u20131318. https:\/\/doi.org\/10.1378\/CHEST.11-0039","journal-title":"Chest"},{"issue":"1 4","key":"6208_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-019-0049-6","volume":"4","author":"ATJ Lee","year":"2019","unstructured":"Lee ATJ, Jones RL, Huang PH (2019) Pazopanib in advanced soft tissue sarcomas. Signal Transduct Target Therapy 2019 4(1 4):1\u201310. https:\/\/doi.org\/10.1038\/s41392-019-0049-6","journal-title":"Signal Transduct Target Therapy 2019"},{"key":"6208_CR13","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1097\/SLA.0B013E31815C2A70","volume":"246","author":"JP Lerut","year":"2007","unstructured":"Lerut JP, Orlando G, Adam R et al (2007) The place of liver transplantation in the treatment of hepatic epitheloid hemangioendothelioma: report of the European liver transplant registry. Ann Surg 246:949\u2013957. https:\/\/doi.org\/10.1097\/SLA.0B013E31815C2A70","journal-title":"Ann Surg"},{"key":"6208_CR14","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1097\/PAS.0000000000001487","volume":"44","author":"A Righi","year":"2020","unstructured":"Righi A, Sbaraglia M, Gambarotti M et al (2020) Primary vascular tumors of bone: A monoinstitutional morphologic and molecular analysis of 427 cases with emphasis on epithelioid variants. Am J Surg Pathol 44:1192\u20131203. https:\/\/doi.org\/10.1097\/PAS.0000000000001487","journal-title":"Am J Surg Pathol"},{"key":"6208_CR15","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/S41379-019-0368-8","volume":"33","author":"E Rosenbaum","year":"2020","unstructured":"Rosenbaum E, Jadeja B, Xu B et al (2020) Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets. Mod Pathol 33:591\u2013602. https:\/\/doi.org\/10.1038\/S41379-019-0368-8","journal-title":"Mod Pathol"},{"key":"6208_CR16","doi-asserted-by":"publisher","unstructured":"Sardaro A, Bardoscia L, Petruzzelli MF, Portaluri M (2014) Epithelioid hemangioendothelioma: an overview and update on a rare vascular tumor. Oncol Rev 8. https:\/\/doi.org\/10.4081\/ONCOL.2014.259","DOI":"10.4081\/ONCOL.2014.259"},{"key":"6208_CR17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.32074\/1591-951X-213","volume":"113","author":"M Sbaraglia","year":"2021","unstructured":"Sbaraglia M, Bellan E, Dei Tos AP (2021) The 2020 WHO classification of soft tissue tumours: news and perspectives. Pathologica 113:70\u201384. https:\/\/doi.org\/10.32074\/1591-951X-213","journal-title":"Pathologica"},{"key":"6208_CR18","doi-asserted-by":"publisher","first-page":"OF1","DOI":"10.1158\/1078-0432.CCR-23-3817","volume":"30","author":"SM Schuetze","year":"2024","unstructured":"Schuetze SM, Ballman KV, Heise R et al (2024) A Single-Arm phase 2 trial of Trametinib in patients with locally advanced or metastatic epithelioid hemangioendothelioma. Clin Cancer Res 30:OF1\u2013OF9. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3817","journal-title":"Clin Cancer Res"},{"key":"6208_CR20","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1245\/S10434-016-5331-Z","volume":"23","author":"S Stacchiotti","year":"2016","unstructured":"Stacchiotti S, Provenzano S, Dagrada G et al (2016) Sirolimus in advanced epithelioid hemangioendothelioma: A retrospective Case-Series analysis from the Italian rare Cancer network database. Ann Surg Oncol 23:2735\u20132744. https:\/\/doi.org\/10.1245\/S10434-016-5331-Z","journal-title":"Ann Surg Oncol"},{"key":"6208_CR19","doi-asserted-by":"publisher","unstructured":"Stacchiotti S, Miah AB, Frezza AM et al (2021a) Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. https:\/\/doi.org\/10.1016\/J.ESMOOP.2021.100170\/ATTACHMENT\/7FB0D4F8-DE30-420A-B394-8D9487F6742E\/MMC4.DOC. ESMO Open 6:","DOI":"10.1016\/J.ESMOOP.2021.100170\/ATTACHMENT\/7FB0D4F8-DE30-420A-B394-8D9487F6742E\/MMC4.DOC"},{"key":"6208_CR21","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/CNCR.33247","volume":"127","author":"S Stacchiotti","year":"2021","unstructured":"Stacchiotti S, Simeone N, Lo Vullo S et al (2021b) Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A case-series analysis within the Italian rare Cancer network. Cancer 127:569\u2013576. https:\/\/doi.org\/10.1002\/CNCR.33247","journal-title":"Cancer"},{"key":"6208_CR22","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WTA Van Der Graaf","year":"2012","unstructured":"Van Der Graaf WTA, Blay JY, Chawla SP et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379:1879\u20131886. https:\/\/doi.org\/10.1016\/S0140-6736(12)60651-5","journal-title":"Lancet"},{"key":"6208_CR23","doi-asserted-by":"publisher","first-page":"OF1","DOI":"10.1158\/1078-0432.CCR-24-1628\/746989","volume":"30","author":"BA Van Tine","year":"2024","unstructured":"Van Tine BA, Haarberg S (2024) Is it time to resist using RECIST as a primary endpoint for rare tumor trials?? Clin Cancer Res 30:OF1\u2013OF2. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1628\/746989\/AM\/IS-IT-TIME-TO-RESIST-USING-RECIST-AS-A-PRIMARY.","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06208-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06208-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06208-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T02:50:38Z","timestamp":1747104638000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06208-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["6208"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06208-8","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,26]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Internal Review Board and the Ethical Review Committee at the Ludwig Maximilians University (LMU) Hospital, Munich, Germany, approved the protocol of this research project (Protocol Nr. 23\u20130998). The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable due to the irreversibly anonymized dataset.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"150"}}